NCT04461587已完成2 期
Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis Associated With Radiographic and Functional Impairment to Examine the Reduction in Progression of Disease, Reduction of Exacerbation Rates and Possible Reduction of Inflammatory Biomarkers as an Index of Clinical Response.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Forced Vital Capacity (FVC)
研究概览
简要总结
Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis (black lung) with pulmonary fibrosis (scarring of the lung).
详细描述
Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis with pulmonary fibrosis associated with radiographic and functional impairment to examine the reduction in progression of disease, reduction of exacerbation rates and possible reduction of inflammatory biomarkers as an index of clinical response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide informed consent and to comply with study protocol
- •Coal miners between the ages 40 to 79 years of age at visit 1with a minimum of 15 years in a coal mining environment
- •Chest CT Scan or Chest Xray (within 6 months) confirming diagnosis of CWP, complicated black lung disease/progressive massive fibrosis will be recorded. If CT not available must be obtained at Visit
- •Evidence of Loss of lung function defined by decline in FEV1 or FVC or DLCO of 5% within the past 36 months prior to enrollment.
- •FEV1 ≤ 75% or FVC ≤ 80% or DLCO ≤ 70% or abnormal 6MWT with oxygen desaturation of 4% or greater than resting at screening or within past 6 months.
- •Former smokers and current smokers will be enrolled if documented evidence of CWP/PMF is present and meet PFT guidelines. Current smokers will be given smoking cessation counseling at each visit due to the effect on pirfenidone concentration and efficacy.
排除标准
- •History of prior therapy with Esbriet or Ofev (pirfenidone or nintedanib)
- •Recent hospitalization (within 30 days prior to screening) for respiratory decompensation.
- •Patients using monoclonal antibody therapy or immunosuppressive therapy for other disease process will be excluded, except for the following:
- •Daily prednisone up to 10 mg daily (prescribed for lung disease or rheumatoid arthritis) will be permitted. Chronic use for 3 months prior to enrollment will be documented.
- •Methotrexate for rheumatoid arthritis will be permitted as long as chronic use for 6 months prior to enrollment is documented.
- •Elevation of liver function test at screening documenting AST, ALT or total bilirubin > 3 x ULN or ALP > 2.5 x ULN.
- •Patients who have other pulmonary pathology such as lung cancer, active tuberculosis or atypical mycobacterial infection requiring treatment.
- •Patients with recurrent malignancy requiring chemotherapy or radiation therapy. Individuals with a prior diagnosis of localized skin cancer, prostate cancer, localized bladder cancer will not be excluded unless undergoing active treatment. Patients with a prior diagnosis of malignancy treated greater than 5 years ago will be considered for enrollment.
- •History of alcohol or drug abuse that would impair or risk the patient's full participation in the drug study in the opinion of the investigator
- •Use of any investigational therapy within 4 weeks of enrollment.
- •Individuals with clinically significant unstable cardiac disease (ejection fraction ≤35%) or complex arrhythmias per PI discretion. Chronic atrial fibrillation will be permitted if heart rate is controlled. Historical values of ejection fraction will be accepted.
- •Individuals with poorly controlled diabetes per PI discretion (Hemoglobin A1c >9). Historical values will be accepted.
- •Pregnancy or lactation.
研究组 & 干预措施
Pirfenidone [Esbriet]
Experimental
Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:
- Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)
- Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)
- Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment.
干预措施: Pirfenidone (Drug)
结局指标
主要结局
Forced Vital Capacity (FVC)
时间窗: 12 months minimum
Primary objective for this study is to determine the rate of decline ( relative change in FVC (% and ml) in patients with coal workers' pneumoconiosis (Black Lung) with pulmonary fibrosis (CWP/PMF) during treatment with pirfenidone (Esbriet®).
次要结局
- Forced Expiratory Volume in 1 second (FEV1)(12 months minimum)
- Diffusing capacity of the lung for carbon monoxide (DLCO)(12 months minimum)
- 6 minute walk test(12 months minimum)
- Chest CT(12 months)
- Inflammatory biomarkers(12 months minimum)
- St. George's Respiratory Questionnaire (SGRQ)(12 months minimum)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity PneumonitisHypersensitivity PneumonitisNCT04675619Zagazig University40
尚未招募
不适用
Pirfenidone Use in Asbestosis Patients: Efficacy and PrognosisAsbestosisNCT05133453Cairo University40
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS.progressive massive fibrosisMedDRA version: 20.0Level: PTClassification code 10040678Term: SilicosisSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: PTClassification code 10036805Term: Progressive massive fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-002701-94-ESFundación para la Gestión de la Investigación Biomédica de Cádiz18
进行中（未招募）
4 期
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaNovel Coronavirus-induced Lung FibrosisNCT04856111Post Graduate Institute of Medical Education and Research, Chandigarh48
已完成
2 期
Pirfenidone and Advanced Liver Fibrosis.Liver FibrosisChronic Liver DiseaseNCT04099407Grupo Mexicano para el Estudios de las Enfermedades Hepaticas122